NEW YORK, May 19 (Reuters) - Johnson & Johnson said six-month study data showed its new experimental stent was better than Boston Scientific's Taxus at preventing re-growth of tissue within the tiny ...

, said its CoStar drug-coated stent failed to meet the main goal of a recent study pitting it against a competing product. Taxus Express 2. During the study, the CoStar failed to be proven at least as ...

Amid falling global stent sales, Johnson & Johnson Medical Middle East has stepped out to defend use of its first-generation drug-eluting stent (DES) Cypher and third-generation stent Cypher Select.

A Johnson & Johnson (NYSE:JNJ) subsidiary allegedly issued a sham recall of its drug-eluting CoStar coronary stent and spiked a distribution deal with Biotronik AG that cost the German medical device ...

The patency rate at 6 months was higher for the silicone-coated metallic stent vs double-J stent. A silicone-covered metallic stent maintains patency better than a double-J stent in patients with ...

A federal judge has found that Johnson & Johnson's Cypher did not infringe patents held by Boston Scientific covering the way stents are coated, Bloomberg News reports. U.S. District Judge Sue ...

Johnson & Johnson's Cordis unit sued Boston Scientific Corp., claiming its Promus drug-coated stent wrongfully uses three of Cordis' patents. J&J, the world's largest health-products company, asked ...